Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06522828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

StatusRecruiting
PhasePhase 2
Started2024-10-10
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 21, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2024-10-17
Not Yet Recruiting→Recruiting Study Status, Oversight, Conditions, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-08→confirmed 2024-10-10
Study sites1 entry, revised
ZhouChongqing QiCancer Hospital
2024-07-29
Study Identification, Study Status v1
Study title-8 characters
A Phase 2 Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
2024-07-22
Original filing
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Trial Details
NCT Number NCT06522828
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Enrollment 80 participants
Start Date 2024-10-10
Primary Completion 2025-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2024-10-21